龟井谦一郎课题组

导师简介

教育经历：

2016.9 – 2020.12 博士（硕博连读）bv伟德国际1946药剂学

2012.9 – 2016.7 学士，bv伟德国际1946基础药学基地班

工作经历：

2021.12 – 至今 特聘副教授，伟德国际victor1946

杂志任职：

1、2021 – 2022，《Acta Materia Medica》青年编委

2、2023 – 至今，《Asian Journal of Pharmaceutical Science》青年编委

荣誉奖励：

第一届药物递释青年学者奖

第一届全国博士后创新创业大赛优胜奖

沈阳市自然科学学术成果奖一等奖

执教课程：

2023级硕士研究生化学靶向药物递送，主讲，bv伟德国际1946

2020级基础药学基地班生物药剂学与药物动力学实验，主讲，bv伟德国际1946

《生物药剂学与药物动力学》，主讲，bv伟德国际1946

主要研究方向（导师）

方向一：口服药物递送

方向二：智能药物纳米递送系统

方向三：应用器官芯片进行药物递送系统评价

导师主持、参与的科研项目（含科研获奖等情况）

1.搭载类脂滴前药纳米粒的仿生脂肪细胞外泌体的构建及肝癌精准靶向递送的研究，国家自然科学基金青年科学基金项目，基金编号82104109（负责人）

2.核壳前药免疫脂质体用于中继放大固有免疫信号治疗实体肿瘤的机制研，辽宁省自然科学基金计划面上项目，基金编号2025-MS-269（负责人）

3.安全高效的位阻二硫键桥连的卡巴他赛脂质口服前药的研究，辽宁省自然科学基金博士科研启动项目，基金编号2022-BS-158（负责人）

4.铁死亡协同并增敏的四价铂前药自组装纳米给药系统的构建，辽宁省教育厅基础科研项目（青年人才），基金编号LJKZ0940（负责人）

5.bv伟德国际1946高层次人才引进科研启动项目（负责人）

6.基于类脂前药的紫杉醇高端口服制剂的研发，克服递药屏障高端制剂全国重点实验室开放课题，基金编号2024-KFB-003（负责人）

7.紫杉醇前药的初步药效学研究，企业技术服务项目，基金编号202104152（负责人）

代表性论文（导师）

1.Yixin Sun, Baoyuan Zhang, Jiayao Wang, Xin Li, Zhonggui He, Chutong Tian＊, Bingjun Sun＊, Jin Sun＊. Robust antitumor treatment driven by lock-and-key biorecognition of dynamic cyclic diselenide-guided chiral prodrug self-assembly, Cell Chemical Biology, 2025, 32, 1013-1027. (IF=7.2)

2.Chutong Tian, Wenjing Ma, Jianbin Shi, Jia Deng, Zeping Gao, Haowen Tian, Ayumi Kikkawa, Kaho Tanaka, Ronggang Xi, Cong Luo, Xiaobo Wang＊, Ken-ichiro Kamei＊. A self-motivated carrier free nanoplatform for synergistic photodynamic and ferroptosis-based therapy for targeted antitumor treatment, Nano Research, 2025, 18, 94907374. (IF=9.0)

3.Jia Deng, Jianbin Shi, Dan Li, Xue Jiao, Jinrui Liu, Haowen Tian, Na Liu, Cong Luo, Ken-ichiro Kamei, Chutong Tian＊. Cancer-targeting drug conjugates drives a new era in precise cancer treatment, Chinese Chemical Letters, 2025, 110960. (IF=8.9)

4.Yu Qin, Na Liu, Fenghui Wang, Zeping Gao, Cong Luo＊, Chutong Tian＊, Ken-ichiro Kamei＊. Self-amplifying ROS-responsive SN38 prodrug nanoparticles for combined chemotherapy and ferroptosis in cancer treatment, Carbon, 2025, 235, 120099. (IF=11.6)

5.Wenxin Zhong, Yalin Xu, Zixuan Wang, Xiyan Wang, Yaqi Li, Jinrui Liu, Can Zhao, Xianbao Shi,Zhonggui He, Bingjun Sun＊, Chutong Tian＊. Dual role of triglyceride structures facilitates anti-tumor drug delivery: Both as a self-assembling module and a responsive module, Journal of Colloid and Interface Science, 2025, 678, 24-34. (IF=9.7)

6.Jianbin Shi, Wenjing Ma, Jia Deng, Shunzhe Zheng, Fengli Xia, Xinying Liu, Ayumi Kikkawa, Kaho Tanaka, Ken-ichiro Kamei＊, Chutong Tian＊. Self-assembled hyaluronic acid nanomicelle for enhanced cascade cancer chemotherapy via self-sensitized ferroptosis, Carbohydrate Polymers, 2024, 343, 122489. (IF=12.5)

7.Shunzhe Zheng, Meng Li, Wenqian Xu, Jiaxin Zhang, Guanting L, Hongying Xiao, Xinying Liu, Jianbin Shi, Fengli Xi, Chutong Tian＊, Ken-ichiro Kamei＊. Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment, Journal of Controlled Release, 2024, 371, 371-385. (IF=11.5)

8.Xinying Liu, Jiaxin Zhang, Shunzhe Zheng, Meng Li, Wenqian Xu, Jianbin Shi, Ken-ichiro Kamei＊, Chutong Tian＊. Hybrid adipocyte-derived exosome nano platform for potent chemo-phototherapy in targeted hepatocellular carcinoma, Journal of Controlled Release, 2024, 370, 168-181. (IF=11.5)

9.Mingyang Zhang, Yifan Miao, Can Zhao, Tong Liu, Xiyan Wang, Zixuan Wang, Wenxin Zhong, Zhonggui He, Chutong Tian＊, Jin Sun＊. Fine-tuning the activation behaviors of ternary modular cabazitaxel prodrugs for efficient and on-target oral anti-cancer therapy, Asian Journal of Pharmaceutical Sciences, 2024, 19, 100908. (IF=11.9)

10.Shunzhe Zheng, Guanting Li, Jianbin Shi, Xinying Liu, Meng Li, Zhonggui He, Chutong Tian＊, Ken-ichiro Kamei＊, Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy, Journal of Controlled Release, 2023, 361, 819-846. (IF=11.5)